Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies

Muñoz, Javier; Sarosiek, Shayna; Castillo, Jorge J.

doi:10.1093/oncolo/oyac260

Cited by 6 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we emphasized how optimizing the safety and long-term tolerability of BTKis requires a thorough evaluation of each patient’s clinical history before initiating therapy. Additionally, careful attention should be given to patient-reported signs and symptoms observed during the course of treatment [ 13 , 50 , 59 ].…”

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Galitzia,

Maccaferri,

Mauro

et al. 2024

Cancers

View full text Add to dashboard Cite

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton’s Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors (BCL-2is). These agents target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which has led to improved progression-free and overall survival rates. This advancement promises enhanced disease control and potentially normal life expectancy for many patients. However, the journey is not without challenges, as these TAs are associated with a range of adverse events (AEs) that can impact treatment efficacy and patient quality of life. This review focuses on detailing the various AEs related to TA management in CLL, evaluating their frequency and clinical impact. The aim is to present a comprehensive guide to the effective management of these AEs, ensuring optimal tolerability and efficacy of TAs. By reviewing the existing literature and consolidating findings, we provide insights into AE management, which is crucial for maximizing patient outcomes in CLL therapy.

show abstract

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Galitzia,

Maccaferri,

Mauro

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The study contained a particular cohort of patients with intolerance to ibrutinib and/or acalabrutinib, who constitute up to 40% of patients with relapsed/refractory chronic lymphocytic leukemia. 2 Given the availability of several covalent and non-covalent BTK inhibitors, questions regarding their optimal sequencing are becoming increasingly relevant also for routine care. National and international treatment guidelines primarily recommend a switch to a different class of agents, e.g.…”

mentioning

confidence: 99%